With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Is the Neulasta Market Poised for Significant Growth? The Neulasta market has experienced considerable expansion in recent years, with a strong historic compound annual growth rate (HCAGR). .The ...

As Merck & Co. hunts for an ideal spot to set up a new commercial facility, Delaware is looking to bolster its odds with a cash sweetener. Monday, Delaware’s state investment board approved a $ ...

Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...

Piscataway, N.J., United States: Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection ...

Mer­ck said its “once-in-a-life­time” drug Keytru­da could be sub­ject to price re­duc­tions un­der the In­fla­tion Re­duc­tion Act, which would lead to a … ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...

Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication developed by Merck that has raked in more than $130 billion in sales for the ...